MAPK13

Across TCGA pan-cancer cohorts, MAPK13 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MAPK13 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MAPK13 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAPK13 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

UCEC, LSCC, and CCRCC are the cancer types where MAPK13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	II,III,IV	0.919	0.379	.006	30	view →
LSCC	OS	Quartile	All	0.957	0.663	.002	26	view →
CCRCC	OS	Median	II,III,IV	1.000	0.823	.007	24	view →
PDAC	DFS	Quartile	II,III,IV	0.511	0.206	.001	13	view →
HNSC	DFS	Tertile	III,IV	0.789	0.483	.012	7	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LUAD	DFS	Tertile	All	1.000	0.730	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MAPK13–UCEC (DFS)

Open the UCEC breakdown →